Sherlock Biosciences, Inc.

Sherlock Biosciences, Inc. , based in the US, specializes in molecular diagnostics, delivering rapid and precise detection solutions for DNA and RNA using innovative CRISPR-based technologies to enhance healthcare accessibility. Sherlock Biosciences focuses on developing advanced molecular diagnostics. Founded in 2019, the company is headquartered in Watertown, Massachusetts, US.

The co-founders include David Walt, Jonathan Gootenberg, Omar Abudayyeh, and the current CEO is Rahul Dhanda. The company has successfully closed 7 funding deals, with the most recent being a Series B round in December 2024, raising USD 80. 00 mn from lead investor Novalis LifeSciences and others including Albany Capital, Catalio Capital Management, Gaingels, Good Ventures, and Illumina Ventures. The total amount raised by the company amounts to USD 80.

00 mn, with a current valuation of USD 168. 52 mn. Sherlock Biosciences specializes in molecular diagnostics, focusing on the rapid and accurate detection of DNA and RNA through its proprietary technologies, SHERLOCK™ and INSPECTR™. These platforms utilize CRISPR and synthetic biology for point-of-need testing, enhancing healthcare accessibility.

The company aims to democratize testing, making personalized healthcare solutions feasible across various settings, from remote clinics to home testing. Its client base includes healthcare providers, laboratories, and end-users seeking timely health-related answers. Sherlock operates in North America, Europe, and emerging markets in Asia and Africa, responding to the increasing demand for accessible diagnostics. Sherlock Biosciences generates revenue through a direct-to-consumer model and partnerships with healthcare providers and laboratories.

The company markets its diagnostic products at varying prices based on testing complexity and capabilities. Clients typically purchase diagnostic kits or subscribe for ongoing access to testing technologies. Partnerships may include bulk purchasing agreements or service contracts, ensuring that Sherlock's innovative products reach a wide audience in both established and developing markets. The acquisition of Sherlock Biosciences by OraSure Technologies Inc.

in December 2024 allows OraSure to broaden its diagnostic offerings by incorporating Sherlock's advanced molecular testing platform. This platform is capable of providing rapid, affordable self-tests for sexually transmitted infections and other health conditions. Future product launches and specific geographic expansions are expected to be outlined as part of the integration strategy following this acquisition.